PBMs’ Role in 340B Program Comes Under Microscope
-
May 22, 2025
Amid policymakers’ ongoing scrutiny of the PBM industry, an April report from a key Senate committee likely added more fuel to the criticism by highlighting how vertically integrated health care giants like CVS Health Corp. reap increasing profits from the 340B Drug Pricing Program.
Further complicating matters, a new court ruling thwarts — at least temporarily — a rebate model created by drugmakers that one expert says could have added much-needed transparency to PBMs’ role in 340B.
Read more© 2025 MMIT

The Latest
Meet Our Reporters
Meet Our Reporters
GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND
Sign up for publications to get unmatched business intelligence delivered to your inbox.